Illumina, Inc. (ILMN)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
$218.22-1.55%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
QuarterlyIQ Insights · ILMN
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 9 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $218 ILMN trades at 42× p/e, in line with its 34× p/e peer median — but our blended $168 fair value sits below the price. It's a high-confidence read. Analysts target $155–$235. The flat-multiple read looks rich, but earnings are inflecting up — trailing growth is accelerating and forward estimates confirm — so we've softened our read rather than brand an accelerating name expensive. Even valued only for durable growth at sustainable margins, it's worth about $248 — above today's price, so the premium reflects that growth case, not pure multiple expansion. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $200.00 | — | — | Analyst | high |
| graham number | 12M | $46.36 | — | — | TTM | high |
| Peer EV/EBITDA | 12M | $45.54 | 18.0 | 2.15 | TTM | high |
| Peer P/E | 12M | $174.60 | 33.9 | 5.15 | TTM | high |
| Peer P/S |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 10% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
$155.00 – $235.00 (median $200.00) · 13 analysts · as of 2026-09-03
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks more expensive than peers.
Richer than its own typical valuation.
Trailing four: 2025-Q2, 2025-Q3, 2026-Q1, 2026-Q2
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
| 12M |
| $167.58 |
| 5.7 |
| 29.37 |
| TTM |
| high |
| PEG | 12M | $351.50 | 68.3 | 5.15 | TTM | high |
| residual income | 12M | $32.54 | — | — | TTM | high |
| Own P/E history | 12M | $194.58 | 37.8 | 5.15 | TTM | high |
| triangulated | 12M | $186.67 | 33.9 | 5.51 | Triangulated | high |
| Peer P/E | 3Y | $212.15 | 33.9 | 6.26 | Analyst | medium |
| Peer P/S | 3Y | $188.44 | 5.7 | 33.02 | guidance | medium |
| PEG | 3Y | $427.08 | 68.3 | 6.26 | Analyst | medium |
| Own P/E history | 3Y | $236.43 | 37.8 | 6.26 | Analyst | medium |
| Peer P/E | 5Y | $219.49 | 33.9 | 6.47 | Analyst | high |
| Peer P/S | 5Y | $194.95 | 5.7 | 34.16 | guidance | high |
| PEG | 5Y | $441.85 | 68.3 | 6.47 | Analyst | high |
| Own P/E history | 5Y | $244.60 | 37.8 | 6.47 | Analyst | high |